Although the specific relationship between the cholinergic system and AD ferroptosis is not clear, as research deepens, cholinesterase inhibitors, M1/M4 muscarinic receptor agonists, and presynaptic choline transporters are being developed, which may help alleviate the progression of AD ferroptosis and improve clinical symptoms such as cognitive disorders, memory impairments, and spatial disorientation. This evidence concerns the gene BCHE and Alzheimer disease.